Nebula Research & Development LLC decreased its position in shares of The Allstate Co. (NYSE:ALL - Free Report) by 61.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,614 shares of the insurance provider's stock after selling 12,194 shares during the period. Nebula Research & Development LLC's holdings in Allstate were worth $1,468,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of ALL. Apella Capital LLC lifted its position in shares of Allstate by 1.9% during the 4th quarter. Apella Capital LLC now owns 3,231 shares of the insurance provider's stock valued at $623,000 after acquiring an additional 60 shares during the period. Intrust Bank NA boosted its holdings in shares of Allstate by 0.5% in the 4th quarter. Intrust Bank NA now owns 12,135 shares of the insurance provider's stock valued at $2,340,000 after purchasing an additional 61 shares in the last quarter. Perigon Wealth Management LLC lifted its position in shares of Allstate by 2.1% during the 4th quarter. Perigon Wealth Management LLC now owns 2,990 shares of the insurance provider's stock worth $571,000 after buying an additional 62 shares during the last quarter. Mather Group LLC. boosted its stake in Allstate by 1.7% in the fourth quarter. Mather Group LLC. now owns 3,616 shares of the insurance provider's stock valued at $697,000 after buying an additional 62 shares in the last quarter. Finally, Angeles Wealth Management LLC grew its position in Allstate by 4.6% in the fourth quarter. Angeles Wealth Management LLC now owns 1,403 shares of the insurance provider's stock valued at $270,000 after acquiring an additional 62 shares during the last quarter. Institutional investors own 76.47% of the company's stock.
Analysts Set New Price Targets
A number of analysts have weighed in on ALL shares. Keefe, Bruyette & Woods cut their target price on shares of Allstate from $240.00 to $228.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. StockNews.com downgraded Allstate from a "buy" rating to a "hold" rating in a research report on Friday, April 18th. Evercore ISI boosted their price target on Allstate from $227.00 to $230.00 and gave the stock an "outperform" rating in a report on Thursday. Barclays dropped their price objective on shares of Allstate from $183.00 to $172.00 and set an "underweight" rating for the company in a report on Friday, April 11th. Finally, JPMorgan Chase & Co. upped their price target on shares of Allstate from $217.00 to $222.00 and gave the company an "overweight" rating in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $221.60.
Read Our Latest Stock Report on ALL
Insider Buying and Selling at Allstate
In other news, CFO Jesse E. Merten sold 40,102 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $186.53, for a total transaction of $7,480,226.06. Following the completion of the transaction, the chief financial officer now directly owns 18,115 shares in the company, valued at $3,378,990.95. This trade represents a 68.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.80% of the company's stock.
Allstate Trading Down 1.4 %
Shares of Allstate stock traded down $2.82 during trading on Thursday, reaching $195.57. 1,399,047 shares of the stock were exchanged, compared to its average volume of 1,620,225. The Allstate Co. has a 1 year low of $156.66 and a 1 year high of $212.91. The firm has a market cap of $51.85 billion, a price-to-earnings ratio of 11.50, a price-to-earnings-growth ratio of 1.01 and a beta of 0.36. The company has a quick ratio of 0.40, a current ratio of 0.36 and a debt-to-equity ratio of 0.42. The stock's fifty day moving average is $198.15 and its 200 day moving average is $194.79.
Allstate (NYSE:ALL - Get Free Report) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $3.53 EPS for the quarter, missing the consensus estimate of $3.98 by ($0.45). Allstate had a return on equity of 28.20% and a net margin of 7.28%. The company had revenue of $14.30 billion during the quarter, compared to analysts' expectations of $16.41 billion. During the same period in the prior year, the business posted $5.13 earnings per share. The company's revenue for the quarter was up 7.8% on a year-over-year basis. As a group, equities research analysts expect that The Allstate Co. will post 18.74 earnings per share for the current fiscal year.
Allstate Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Monday, March 10th were paid a dividend of $1.00 per share. The ex-dividend date of this dividend was Monday, March 10th. This represents a $4.00 annualized dividend and a yield of 2.05%. This is a positive change from Allstate's previous quarterly dividend of $0.92. Allstate's payout ratio is presently 23.54%.
Allstate declared that its Board of Directors has initiated a stock repurchase program on Wednesday, February 26th that permits the company to repurchase $1.50 billion in shares. This repurchase authorization permits the insurance provider to purchase up to 3% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board believes its shares are undervalued.
About Allstate
(
Free Report)
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. It operates in five segments: Allstate Protection; Protection Services; Allstate Health and Benefits; Run-off Property-Liability; and Corporate and Other segments.
Featured Stories

Before you consider Allstate, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allstate wasn't on the list.
While Allstate currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.